Human NKG2C⁺ adaptive NK cells for Cancer immunotherapy

Area of Science:

• Immunology
• Oncology
• Cell Therapy

Background:

• Natural killer (NK) cells are crucial for innate immunity and tumor immunosurveillance.
• NKG2C+ adaptive NK cells, induced by human cytomegalovirus (HCMV), exhibit memory-like properties with therapeutic potential.
• Early trials show safety and efficacy of NK cells in hematological malignancies and solid tumors.

Purpose of the Study:

• To explore the therapeutic potential of NKG2C+ adaptive NK cells.
• To investigate methods for efficient ex vivo expansion and functional augmentation of these cells.
• To identify novel strategies for next-generation cancer immunotherapy.

Main Methods:

• Utilized a "super-donor" selection strategy for NK cell expansion.
• Combined NKG2C-specific activation with cytokine stimulation for efficient ex vivo expansion.
• Integrated synthetic immunology (NK cell engagers, engineered receptors), epigenetic modulation, and metabolic reprogramming.

Main Results:

• Demonstrated efficient ex vivo expansion of NKG2C+ adaptive NK cells.
• Showcased comprehensive augmentation of antitumor functions through integrated approaches.
• Preclinical models and early clinical trials indicate therapeutic promise and a favorable safety profile.

Conclusions:

• NKG2C+ adaptive NK cells represent a promising cell subset for cancer immunotherapy.
• Advanced expansion and functional enhancement strategies can unlock their full therapeutic potential.
• These findings pave the way for novel, next-generation cancer immunotherapies.